1-ethyl-2-azetidinemethanamine | 1314924-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 1-ethyl-2-azetidinemethanamine
• 英文别名: (1-Ethylazetidin-2-yl)methanamine
• CAS: 1314924-87-2
• 化学式: C₆H₁₄N₂
• mdl: MFCD19207776
• 分子量: 114.191
• InChiKey: VCGBXNXXMFHOBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,4-二溴丁酸甲酯 生成 1-ethyl-2-azetidinemethanamine
  参考文献：
  名称：

  Aminoalkyl-substituted azetidine platinum(II) complexes

  摘要：

  具有中性双齿氨基烷基取代环烷胺配体和溴、氯、碘、硝酸根、草酸根或马拉酸根的顺式铂（II）的四配位方平面配合物具有抗微生物活性，同时对移植的L1210和P388小鼠白血病细胞系具有活性。

  公开号：

  US04970324A1

文献信息

• Aminoalkyl-substituted cycloalkylamine platinum(II) complexes
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0228077A2

  公开（公告）日：1987-07-08

  Square-planar four-coordinate complexes of cis-platinum(II) with neutral bidentate aminoalkyl-substituted cy- cloalkylamine ligands and bromo-, chloro-, iodo-, nitrato-, oxalato-, or malonatoligands possess antimicrobial activity as well as activity against transplanted L1210 and P388 murine leukemia cell lines.

  顺式铂(II)与中性双齿氨基烷基取代的环烷基胺配体以及溴、氯、碘、硝酸根、草酸根或丙二酸根配体的方形平面四配位配合物具有抗菌活性以及对移植的 L1210 和 P388 小鼠白血病细胞系的活性。
• NOVEL SULFONAMIDEUREA COMPOUNDS
  申请人：Inflazome Limited

  公开号：EP3836917A1

  公开（公告）日：2021-06-23
• US4970324A
  申请人：——

  公开号：US4970324A

  公开（公告）日：1990-11-13
• US5116831A
  申请人：——

  公开号：US5116831A

  公开（公告）日：1992-05-26
• [EN] NOVEL SULFONAMIDEUREA COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE SULFONAMIDE URÉE
  申请人：INFLAZOME LTD

  公开号：WO2020035464A1

  公开（公告）日：2020-02-20

  The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which they are attached may form a 3- to 12-membered optionally substituted cyclic group; and R2 is a cyclic group substituted at the oposition, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.